Brc-Abl

Shah, N. P., Nicoll, J., Nagar, B., et al. (2002) Multiple BRC-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125. 

Imatinib is indicated for chronic myelocytic leukemia. Il acts by inhibiting the tyro.sine kina.se BRC-ABL. thus ptc-venting it from arresting apoptosis. This agent is well ab-.sorbed orally, and the maximum concentration in blood r achieved within 2 to 4 hours. Il is 95% bound to. senim proteins. The major metabolite results from N-demelh l-alion. Elimination half-times are 18 hours for imatinib anl 40 hours for the N-demelhyl metabolite. Excretion is mainly in feces. 

The WST for Abl and its paralogs is shown in Fig. 7.5c. We have also restricted the WST computation to the hydrogen bonds/dehydrons in Brc-Abl which become wrapped by Gleevec upon association. Adopting this restricted measure, the closest proteins to Brc-Abl become Lck, C-Kit, and PDGFR, precisely the alternative Gleevec targets with reported structure. 

In order to enhance affinity and selectivity for Brc-Abl, we modified the inhibitor methylating at positions I and II (Fig. 7.5d). The synthesis of the wrapping prototype recapitulates imatinib synthesis [38], as described in [39], To test whether the specificity and affinity for Brc-Abl improved, we conducted a spectrophotometric kinetic assay to measure the phosphorylation rate of peptide substrates in the presence of the kinase inhibitor at different concentrations. This assay couples production of adenosine diphosphate (ADP), the byproduct of downstream phosphorylation, with the concurrent detectable oxidation of reduced nicotinamide adenosine dinucleotide (NADH). The oxidation results upon transfer of phosphate from PEP (phospho-enolpyruvate) to ADP followed by the NADH-mediated reduction of PEP to lactate. Thus, phosphorylation activity is monitored by the decrease in 340 nm absorbance due to the oxidative conversion NADH->-NAD+ [34, 39]. 

As indicated in Fig. 7.5e, the spectrophotometric assay revealed the inhibition of the unphosphorylated Brc-Abl by the wrapper of the 249-252 and 300-316 dehydrons (the I- and II-methylation product) improved over Gleevec levels. Furthermore, the inhibitory impact of the dehydron wrapper became selective for Brc-Abl vis-a-vis C-Kit and Lck. Dehydrons 249-252 and 300-316 are absent in the latter kinases and, consistently, the drug designed to better wrap them has very low inhibitory impact against C-Kit and Lck. 

Pre-immunization of bone marrow transplant donors with BRC/ABL p210 protein. In patients with BCR/ABL leukemia cells, anti-leukemia cell reactive antibodies and immune T cells are generated (too weak to induce remission). Bone marrow donors pre-immunized with p210 protein (nucleic acid-free) would provide not only rescue for hematopoiesis, but antibodies co-acting with patient s NK cells, and immune T cells both cytolytic to BRC/ABL leukemia cells. Proposals are not known to have had acted upon at NCI at MD Anderson. ... 

As a consequence, the previous situation may be expressed as the interaction between the Food and Package system [2] and the aware Consumer [3]. In effect, every food company should be able to collect, satisfy and anticipate the exigencies of Consumers, as requested by British Retail Consortium (BRC) and International Food Standard (IFS) protocols. These requests are often in accord with existing Regulations with concern to food safety. However, the necessity to foresee the needs of normal people and sensible consumers is highly recommended because of the risk of expensive and intricate class actions. 

---